参考文献/References:
[1] Sun J,Qiao Y,Zhao M,et al.Regional,and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries/territories,1990-2019:a systematic analysis of global burden of disease study 2019[J].BMC Med,2023,21(1):222.
[2] Hacke WK,Ecass I.Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J].N Engl J Med,2008,359(13):1317-1329.
[3] Luo YH,Peng DQ.Residual atherosclerotic cardiovascular disease risk: focus on non-high-density lipoprotein cholesterol[J].J Cardiovasc Pharmacol Ther,2023,28:10742484231189597.
[4] Toprak K,Kaplangoray M,Akyol S,et al.The non-HDL-C/HDL-C ratio is a strong and Independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction[J].Acta Cardiol,2024,79(2):194-205.
[5] Zhao Z,Wang HR,Hou Q,et al.Non-traditional lipid parameters as potential predictors of carotid plaque vulnerability and stenosis in patients with acute ischemic stroke[J].Neurol Sci,2023,44(3):835-843.
[6] Yu WM,Abdul-Rahim AH,Cameron AC,et al.The incidence and associated factors of early neurological deterioration after thrombolysis: results from SITS registry[J].Stroke,2020,51(9):2705-2714.
[7] Kim JM,Moon J,Ahn SW,et al.The etiologies of early neurological deterioration after thrombolysis and risk factors of ischemia progression[J].J Stroke Cerebrovasc Dis,2016,25(2):383-388.
[8] Tschirret O,Moreno Legast G,Mansuy A,et al.Impact of brain atrophy on early neurological deterioration and outcome in severe ischemic stroke treated by intravenous thrombolysis[J].Eur Neurol,2018,79(5/6):240-246.
[9] Zhou HM,Zhang SZ,Sun XT,et al.Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying appraisal of guidelines for research and evaluation II-clinical practice guideline appraisal for lipid management in coronary heart disease[J].J Thorac Dis,2019,11(8):3534-3546.
[10] Heidemann BE,Koopal C,Roeters van Lennep JE,et al.Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia[J].J Clin Lipidol,2023,17(1):112-123.
[11] Ballantyne CM,Ditmarsch M,Kastelein JJ,et al.Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy:a randomized phase 2 trial[J].J Clin Lipidol,2023,17(4):491-503.
[12] Sung SM,Kang YJ,Cho HJ,et al.Prediction of early neurological deterioration in acute minor ischemic stroke by machine learning algorithms[J].Clin Neurol Neurosurg,2020,195:105892.
[13] Guo JH,Wang AX,Wang Y,et al.Non-traditional lipid parameters as potential predictors of asymptomatic intracranial arterial stenosis[J].Front Neurol,2021,12:679415.
[14] Liu Y,Zhang ZW,Xia BL,et al.Relationship between the non-HDLc-to-HDLc ratio and carotid plaques in a high stroke risk population:a cross-sectional study in China[J].Lipids Health Dis,2020,19(1):168.
[15] Wang LB,Han Y,Cao CC,et al.The non-linear Link between non-high-density lipoprotein to high-density lipoprotein ratio and the risk of stroke in middle-aged and older adults in Chinese:a prospective cohort study from the China health and retirement longitudinal study[J].Front Endocrinol(Lausanne),2023,14:1303336.
[16] Han Q,You SJ,Maeda T,et al.Predictors of early versus delayed neurological deterioration after thrombolysis for ischemic stroke[J].Cerebrovasc Dis,2024:1-9.
[17] Barow E,Boutitie F,Cheng B,et al.24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke[J].Eur Stroke J,2021,6(2):168-175.
[18] Liu LP,Zhou HY,Duan WY,et al.Chinese stroke association guidelines for clinical management of cerebrovascular diseases(second edition)(excerpt)--chapter four clinical management of ischaemic cerebrovascular diseases[J].Journal volume&,2023,18(8):1673-5765.
[19] Chung JW,Kim N,Kang J,et al.Blood pressure variability and the development of early neurological deterioration following acute ischemic stroke[J].J Hypertens,2015,33(10):2099-2106.